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Oral bioavailability of drug is limited by the factors such as the
membrane permeability, the solubility, the dissolution rate and
so on [1]. In case of a poorly water-soluble drug, its solubility
and dissolution rate is a critical factor for its oral bioavailability.
Among various techniques for enhancing solubility or disso-
lution properties, physical modification of drug products such
as reducing the particle size is one of common approaches [2].
In previous studies, we have succeeded in preparation of nano-
crystal suspensions of poorly water-soluble drugs by using a
high pressure crystallizer (PureNano®).
Cyclodextrins (CyDs) are cyclic oligosaccharides consist-
ing of six to eight glucose units linked by α-1,4-glycosidic
linkage. The potential use of natural CyDs and their syn-
thetic derivatives have been extensively studied to improve
certain properties of the drugs, such as solubility, stability, and/
or bioavailability. One of the most useful applications of CyDs
in dosage form design is enhancing the solubility of poorly
water-soluble drugs by complex formation.
In the present study, we tried to prepare drug nanoparticles
of a poorly water-soluble drug by high pressure crystalliza-
tion method using CyDs or erythritol as additives in freeze-
drying process. Silymarin (SLM) is a functional food ingredient
that has very low aqueous solubility (solubility in water:
50 μg/mL). In the present method, the model drug was dis-
solved in organic solvent, which was mixed with the aqueous
phase under a high pressure. The obtained dispersions were
freeze-dried for further physicochemical characterization of the
obtained powdered nanoparticles.
The nanocrystal of SLM produced with this high pressure
crystallization process exhibited a narrow size distribution.The
particle size of SLM crystals powdered with erythritol or
hydroxypropyl-β-CyD (HP-β-CyD) was observed about 230 nm
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after hydration. When measuring the concentration of SLM in
the dissolution test, SLM/HP-β-CyD showed the maximum su-
persaturated concentration of SLM (100 μg/mL). The plasma
concentration profiles in absorption test in rats with various
SLM nanoparticles samples prepared with this high pressure
crystallization process were shown in Fig. 1. The SLM/HP-β-
CyD nanoparticles exhibited significantly increased AUC0-6 h and
Cmax compared with other SLM nanoparticles. Such a high AUC
value was not observed with SLM/erythritol nanoparticle, where
erythritol was used as a stabilizer instead of HP-β-CyD, and with
physical mixture of SLM and HP-β-CyD. From these results, a
combination of the high pressure crystallization method and
use of HP-β-CyD is useful for the effective production of drug
nanoparticles of SLM showing enhanced dissolution rate and
absorbability.
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Fig. 1 – Blood concentration profile after oral administration
of various SLM nanoparticles in rats.
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